126,727 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by Delta Lloyd Asset Management N.V.

Delta Lloyd Asset Management N.V. bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 126,727 shares of the medical equipment provider’s stock, valued at approximately $16,272,000. Delta Lloyd Asset Management N.V. owned approximately 0.06% of Zimmer Biomet Holdings at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Parkside Financial Bank & Trust boosted its stake in Zimmer Biomet Holdings by 2.7% during the 1st quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after purchasing an additional 22 shares during the period. Bronfman E.L. Rothschild L.P. lifted its stake in shares of Zimmer Biomet Holdings by 25.3% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after acquiring an additional 167 shares during the period. Parallel Advisors LLC lifted its stake in shares of Zimmer Biomet Holdings by 20.8% in the 1st quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after acquiring an additional 199 shares during the period. IHT Wealth Management LLC lifted its stake in shares of Zimmer Biomet Holdings by 28.4% in the 1st quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after acquiring an additional 256 shares during the period. Finally, Sandy Spring Bank lifted its stake in shares of Zimmer Biomet Holdings by 1.7% in the 1st quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after acquiring an additional 20 shares during the period. Institutional investors and hedge funds own 85.48% of the company’s stock.

In related news, VP Tony W. Collins sold 16,986 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.07% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded down 0.45% during midday trading on Friday, reaching $115.47. 1,626,722 shares of the company’s stock were exchanged. The company has a market capitalization of $23.35 billion, a PE ratio of 32.89 and a beta of 1.21. The firm has a 50-day moving average of $114.88 and a 200-day moving average of $120.74. Zimmer Biomet Holdings, Inc. has a 1-year low of $95.63 and a 1-year high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the consensus estimate of $2.10 by ($0.02). The company had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period last year, the company earned $2.02 earnings per share. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.83%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.

Several research firms have weighed in on ZBH. Royal Bank Of Canada restated an “outperform” rating and set a $140.00 target price on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Wells Fargo & Company restated a “market weight” rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Jefferies Group LLC reiterated a “buy” rating and set a $148.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, June 30th. Piper Jaffray Companies reiterated a “buy” rating and set a $135.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a report on Friday, July 28th. Four analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Zimmer Biomet Holdings has a consensus rating of “Hold” and an average price target of $136.75.

TRADEMARK VIOLATION NOTICE: This piece was posted by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/delta-lloyd-asset-management-n-v-invests-16-27-million-in-zimmer-biomet-holdings-inc-zbh/1565799.html.

Zimmer Biomet Holdings Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.